---
title: "Roivant Q4 swings to profit of $355.7 million; revenue falls to $2.52 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287052940.md"
description: "Roivant reported a Q4 net income of $302.99 million, a turnaround from a loss last year, driven by a $770.24 million litigation settlement gain. However, revenue fell 66.71% to $2.52 million, while R&D expenses rose 36.98% to $198.95 million. The company holds $4.3 billion in cash and equivalents, supporting its path to profitability. Roivant anticipates launching brepocitinib in September 2026, with key clinical data expected later in the year."
datetime: "2026-05-20T11:04:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287052940.md)
  - [en](https://longbridge.com/en/news/287052940.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287052940.md)
---

# Roivant Q4 swings to profit of $355.7 million; revenue falls to $2.52 million

-   Roivant posted net income attributable to shareholders of USD 302.99 million for the fourth quarter, swinging from a loss a year earlier. \* Operating income turned positive at USD 415.24 million as the quarter included a USD 770.24 million litigation settlement gain tied to the Moderna agreement. \* Revenue fell 66.71% to USD 2.52 million, while R&D expense climbed 36.98% to USD 198.95 million. \* Cash, cash equivalents and marketable securities totaled USD 4.3 billion at March 31, 2026; the company said this supports runway into profitability. \* Roivant reiterated a late-September 2026 expected launch for brepocitinib in dermatomyositis, with topline Phase 3 data in non-infectious uveitis and Phase 2 mosliciguat data in PH-ILD expected in the second half of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200700PRIMZONEFULLFEED9723696) on May 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [Incyte expands Genesis Molecular AI collaboration, pays USD 120 million upfront](https://longbridge.com/en/news/287060301.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Upsher-Smith launches Restasis generic cyclosporine ophthalmic emulsion 0.05%](https://longbridge.com/en/news/287079790.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)